Better Coronavirus Stock: Moderna or Novavax?

Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) have been taking turns at center stage with their coronavirus vaccine programs. Moderna grabbed investors' attention in March when it became the first drugmaker to test an investigational coronavirus vaccine in humans. Novavax wowed the crowd a few months later when the U.S. government granted it $1.6 billion in support of its coronavirus vaccine candidate. At the time, it was the biggest such award to a vaccine maker.

Year to date, shares of both clinical-stage biotech companies have soared -- over 260% for Moderna and more than 2,300% for Novavax. Since their highs, though, both stocks have given up some of their gains. As the coronavirus vaccine race approaches its final stages, which of these two players represents the best buy right now? To find out, let's take a closer look at each one.

Image source: Getty Images.

Continue reading

Source Fool.com